Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Buendia who wrote (495)	4/17/1998 11:13:00 AM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 2887

Actually ABMI has 100% silicone catheters which compete mainly with Baxter's catheter line. 100% silicone catheters have many advantages but the primary advantage is they will not cause a severe allergic reaction like latex can. As for stainless steel? The use of stainless steel in stents is proving to be a downfall because it lacks the flexibility and expandability of metals like Nitinol. This is a big reason why JNJ has been losing market share in the stent field. AVEI is buying World Medical for their stent products. World Medical's stent product in phase II testing uses Nitinol. American BioMed also is using Nitinol in it's stents. Nitinol is a Nickle Titanium alloy that is flexible, self expanding and extremely strong. Nitinol has tremendous advantages over stainless steel. Looking at the article what I found most interesting were the references to AVEI being a one product company. Even after buying World Medical their product portfolio is very limited. Let me paste an excerpt: "If you've owned shares, it's been a heart-stopping ride because the company basically has had just one product. But this week, the firm announced the acquisition of $62-million World Medical Manufacturing Corp., which makes a complementary device." Basically World Medical was purchased because it has one complimentary device very similar to the stent designs of our own company. AVEI paid $62 million for World Medical and that one product still in phase II testing. ABMI has 27 patents, a much broader product portfolio in R&D, the 100% silicone catheter line, ISO 9001 certification and more OEM contracts coming. It looks as though we may be moving back into the strong buy range again soon. The stock has been trying to base at .65 if that fails anything below it has got to be considered a great buy in my estimation. It's my opinion American BioMed has a much broader portfolio than AVEI even after their buy of World Medical. ABMI will be a big winner in 1998! Go ABMI! Regards, Jeff

To: Buendia who wrote (495)	4/17/1998 11:17:00 AM
From: Aishwarya	Read Replies (1) \| Respond to of 2887

Hi Fielding, The use of Ninitol compound was spurred more by its extremely super elastic capabilities. The results are favorable at different temperatures. Now this translates in to a more physician friendly product and its ease of use with the Stent and Catheter line of products. I believe that Ninitol is superior to steel and only time will tell. JNJ is also employing steel for Palmaz Schatz stent line of products. Check this post and hopefully your question is answered www3.techstocks.com Go ABMI Regards, Sri.